Objectives: A high virological response rate can often be shown to be obtained with PEG-IFN α-2b and ribavirin combination therapy in chronic hepatitis C patients. Viral dynamics have been utilized for the evaluation of antiviral effects, especially the exponential second decay slope, which represents the elimination of infected cells. Methods: Forty-nine patients were randomly assigned to the IFN α-2b group (n = 26) or the PEG-IFN α-2b group (n = 23). Ribavirin was administered equally to both groups. Measuring the serum concentration of HCVRNA, the exponential viral decay during phase 1 and 2 was calculated. Results: The exponential decay slope in phase 2 during the first 2 weeks was greater in the IFN α-2b group than in the PEG-IFN α-2b group; however, from weeks 3 to 4, it was greater in the PEG-IFN α-2b group than in the IFN α-2b group. Interestingly, in the PEG-IFN α-2b group, the exponential decay slope was greater from weeks 3 to 4 after initiating combination therapy than during the weeks 1–2 (p < 0.01), despite administration of the same PEG-IFN α-2b dose (1.5 µg/kg once weekly). Conclusions: In PEG-IFN α-2b and ribavirin combination therapy, elimination of infected cells may be pronounced following an increase in serum ribavirin concentration in chronic hepatitis C patients with genotype 1b infection and a high viral load.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.